statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm PR Newswire STOCKHOLM, May 15, 2024...

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

Notice of annual general meeting of Calliditas Therapeutics AB (publ) Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, May 15, 2024 STOCKHOLM, May 15, 2024...

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China PR Newswire STOCKHOLM, May 14...

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib Calliditas announces positive topline results of Phase 2 head and neck...

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 Calliditas Therapeutics...

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Calliditas Therapeutics to Attend Conferences in April Calliditas Therapeutics to Attend Conferences in April PR Newswire STOCKHOLM, April 9, 2024 STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas...

Calliditas Therapeutics to Attend Conferences in April

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of...

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment Calliditas receives notice of allowance for United States patent application...

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $21.25, but opened at $22.00. Calliditas Therapeutics AB...

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $22.08, but opened at $21.03...

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $22.08

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

Watchers	1,226
52-Wk Low	$15.25
52-Wk High	$29.30

Volume	1,561.00
52-Wk High	$29.30
52-Wk Low	$15.25

CALT Calliditas Therapeutics AB - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community